Claims
- 1. A compound of the formula (I) ##STR28## and physiologically acceptable salts and hydrates thereof, in which one of R.sub.1 and R.sub.2 represent hydrogen, halogen or a C.sub.1-4 alkyl group which may be optionally substituted by hydroxy or C.sub.1-4 alkoxy, and the other represents the group R.sub.4 R.sub.5 NAlk- in which R.sub.4 represents hydrogen, C.sub.1-10 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, ar C.sub.1-6 alkyl, heteroar C.sub.1-4 alkyl, trifluoro C.sub.1-6 alkyl, or C.sub.1-6 alkyl substituted by hydroxy, C.sub.1-6 alkoxy, amino, C.sub.1-6 alkylamino, di C.sub.1-6 alkylamino or C.sub.3-8 cycloalkyl, and R.sub.5 represents hydrogen or a C.sub.1-4 alkyl group or R.sub.4 and R.sub.5 may together with the nitrogen atom to which they are attached, form a pyrrolidino, piperidino, hexamethylenimino, heptamethylenimino, tetrahydropyridino, 4-hydroxypiperidino, 4-C.sub.1-3 alkylpiperidino, morpholino, 2,6-di-C.sub.1-3 alkylmorpholino or thiamorpholino group;
- Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;
- R.sub.3, which may be in either the 2 or 3-position, represents the group ##STR29## where X represents --CH.sub.2 --, --O-- or --S--;
- n represents zero, 1 or 2
- m represents 2, 3 or 4;
- R.sub.7 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, ar C.sub.1-6 alkyl or C.sub.2-6 alkyl substituted by hydroxy or C.sub.1-6 alkoxy; and
- R.sub.8 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, ar C.sub.1-6 alkyl, hydroxy C.sub.1-6 alkyl, acyloxy C.sub.1-6 alkyl, wherein acyl is aroyl or ar C.sub.2-7 alkanoyl, C.sub.1-6 alkanoyl, C.sub.1-6 alkoxy C.sub.1-6 alkyl, aryloxy C.sub.1-6 alkyl, ar C.sub.1-6 alkyloxy C.sub.1-6 alkyl, amino C.sub.1-6 alkyl, C.sub.1-6 alkylamino C.sub.1-6 alkyl, di C.sub.1-6 alkylamino C.sub.1-6 alkyl, hydroxy or C.sub.1-6 alkoxy, or the group NR.sub.10 R.sub.11 where
- R.sub.10 represents hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkyl substituted by hydroxy or C.sub.1-3 alkoxy, C.sub.3-6 alkenyl, ar C.sub.1-6 alkyl, heteroar C.sub.1-6 alkyl, and R.sub.11 represents any of the groups defined for R.sub.10 or may represent COR.sub.12 where R.sub.12 represents hydrogen, C.sub.1-6 alkyl, aryl, ar C.sub.1-6 alkyl, C.sub.1-6 alkoxy, heteroaryl, heteroar C.sub.1-6 alkyl or
- R.sub.11 represents the group SO.sub.2 R.sub.13 where R.sub.13 represents C.sub.1-6 alkyl or aryl or
- R.sub.11 represents the group ##STR30## where E represents oxygen or sulphur, and R.sub.14 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, aryl or ar C.sub.1-6 alkyl or
- R.sub.10 and R.sub.11 taken together represent the group .dbd.CR.sub.15 R.sub.16 where R.sub.15 represents aryl or heteroaryl and R.sub.16 represents hydrogen or C.sub.1-6 alkyl,
- with the provisos that
- where R.sub.2 represents the group R.sub.4 R.sub.5 NAlk then R.sub.3 is in the 2-position;
- where R.sub.2 represents hydrogen then R.sub.3 is in the 3-position; and
- where R.sub.2 represents halogen or C.sub.1-4 alkyl optionally substituted by hydroxy or C.sub.1-4 alkoxy, and R.sub.3 is in the 2-position, then R.sub.8 cannot represent amino C.sub.1-6 alkyl, C.sub.1-6 alkylamino C.sub.1-6 alkyl, di C.sub.1-6 alkylamino C.sub.1-6 alkyl or a group NR.sub.10 R.sub.11.
- 2. A compound according to claim 1, in which the groups R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7 and R.sub.8 have the following meanings:
- R.sub.1 or R.sub.2 (where other than the group R.sub.4 R.sub.5 NAlk): a hydrogen or bromine atom or a C.sub.1-3 alkyl group or a C.sub.1-3 alkoxy C.sub.1-3 alkyl group or a hydroxy C.sub.1-3 alkyl group; or when R.sub.1 or R.sub.2 is the group R.sub.4 R.sub.5 NAlk,
- R.sub.4 : C.sub.1-10 alkyl, C.sub.5-7 cycloalkyl, C.sub.3-6 alkenyl, ar C.sub.1-6 alkyl, wherein the aryl portion is phenyl or phenyl substituted by one or more C.sub.1-3 alkyl, C.sub.1-3 alkoxy or halogen atoms; C.sub.1-4 alkyl substituted by a trifluoromethyl group, hydroxy C.sub.2-4 alkyl, C.sub.1-3 alkoxy C.sub.2-4 alkyl, di-C.sub.1-3 alkylamino C.sub.1-6 alkyl, or heteroaralkyl where the heteroaryl portion represents a furyl, thienyl, pyridyl or thiazolyl ring and the alkylene portion is a methylene, ethylene or propylene grouping; and
- R.sub.5 : hydrogen or a methyl or ethyl group; or
- R.sub.4 R.sub.5 N: pyrrolidino, piperidino, hexamethylenimino, heptamethylenimino, tetrahydropyridino, 4-hydroxypiperidino, 4-C.sub.1-3 alkylpiperidino, morpholino, 2,6-di-C.sub.1-3 alkylmorpholino or thiamorpholino group;
- R.sub.7 : hydrogen, C.sub.1-4 alkyl or hydroxy-C.sub.2-4 alkyl;
- R.sub.8 : hydrogen, hydroxy, C.sub.1-4 alkyl, hydroxy C.sub.1-4 alkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, phenyl C.sub.1-3 alkyl, C.sub.2-4 alkanoyloxy C.sub.1-4 alkyl, amino C.sub.1-4 alkyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, phenyl C.sub.1-3 alkylamino, or a heteroaryl C.sub.1-3 alkylamino group; or represents the group NHCOR.sub.12 where R.sub.12 represents hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, furyl, pyridyl, thiazolyl, thienyl, or phenyl optionally substituted by a C.sub.1-3 alkyl or a C.sub.1-3 alkoxy group; or represents the group NHSO.sub.2 R.sub.13 where R.sub.13 represents C.sub.1-3 alkyl or phenyl optionally substituted by a C.sub.1-3 alkyl or C.sub.1-3 alkoxy group; or represents the group NHCONHR.sub.14 where R.sub.14 is C.sub.1-3 alkyl, C.sub.5-7 cycloalkyl or phenyl optionally substituted by a C.sub.1-3 alkyl or C.sub.1-3 alkoxy group, or represents the group N.dbd.CHR.sub.15 where R.sub.15 is a phenyl or pyridyl group, and Alk is (CH.sub.2 ).sub.p where p is 1, 2 or 3.
- 3. A compound according to claim 1 in which R.sub.3 is in the 3- position and R.sub.1 is the group R.sub.4 R.sub.5 NAlk.
- 4. A compound according to claim 1 in which R.sub.3 is in the 2-position and R.sub.1 is the group R.sub.4 R.sub.5 NAlk.
- 5. A compound according to claim 1 where Alk is methylene.
- 6. A compound according to claim 1, in which R.sub.7 is hydrogen or methyl and R.sub.8 is amino, hydroxy C.sub.1-6 alkyl, C.sub.1-6 alkoxy C.sub.1-6 alkyl, benzyl, formamido, C.sub.1-6 alkanoylamino, amino C.sub.1-6 alkyl, C.sub.1-6 alkanoyloxy C.sub.1-6 alkyl, hydroxy, aroylamino where the aryl portion is phenyl or phenyl substituted with one or more C.sub.1-3 alkyl, C.sub.1-3 alkoxy or halogen atoms; or phenylcarbamoyalmino.
- 7. A compound according to claim 1, corresponding to formula (II), ##STR31## where R.sub.4 and R.sub.5 are methyl groups or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexamethylenimino group; R.sub.7 is hydrogen or methyl, and R.sub.8 is amino, hydroxy C.sub.1-6 alkyl, C.sub.1-6 alkoxy C.sub.1-6 alkyl, benzyl, formamido, C.sub.1-6 alkanoylamino, amino C.sub.1-6 alkyl, C.sub.1-6 alkanoyloxy C.sub.1-6 alkyl, hydroxy, aroylamino wherein the aryl portion is phenyl or phenyl substituted by one or more C.sub.1-3 alkyl, C.sub.1-3 alkoxy or halogen atoms; or phenylcarbamoylamino.
- 8. A compound according to claim 1 which are:
- 1-methyl-N.sup.5 -[2-[[5-[(dimethylamino)methyl]-4-methyl-2-thienylmethyl]thio]ethyl]-1H-1,2,4-triazole-3,5-diamine
- 1-methyl-5-[[2-[[5-(dimethylaminomethyl)-3-thienylmethyl]thio]ethyl]amino]-1H-1,2,4-triazole-3-methanol
- 5-[[2-[[[5-(dimethylaminomethyl)-4-methyl]-2-thienylmethyl]-thio]ethyl]amino]-1-methyl-1H-1,2,4-triazole-3-methanol
- 5-[[2-[[5-(dimethylaminomethyl)-3-thienyl]methyl]thio]ethyl]amino-3-phenylmethyl-1H-1,2,4-triazole, and their physiologically acceptable salts.
- 9. A pharmaceutical composition for the treatment of conditions mediated through H.sub.2 receptors comprising an effective amount of at least one compound according to claim together with at least one pharmaceutically acceptable carrier or diluent and optionally at least one other active ingredient.
- 10. A method of treating a condition mediated through histamine H.sub.2 - receptors which comprises administering to a patient an effective amount of a compound according to claim 1 to relieve said condition.
- 11. A compound according to claim 6 in which R.sub.8 represents amino, hydroxy C.sub.1-6 alkyl, C.sub.1-6 alkanoylamino or benzyl.
- 12. A compound according to claim 1 which is N.sup.5 -[2-[[5-(Dimethylaminomethyl)-3-thienylmethyl]-thio]ethyl]-1-methyl-1H-1,2,4,-triazole-3,-5-diamine.
Priority Claims (2)
Number |
Date |
Country |
Kind |
7936762 |
Oct 1979 |
GBX |
|
8018404 |
Jun 1980 |
GBX |
|
Parent Case Info
This application is a continuation of application Ser. No. 429,135 filed Sept. 30, 1982, which is a continuation of application Ser. No. 199,720 filed Oct. 23, 1980, both now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4318913 |
Clitherow et al. |
Mar 1982 |
|
4323566 |
Clitherow et al. |
Apr 1982 |
|
4536508 |
Clitherow et al. |
Aug 1985 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
429135 |
Sep 1982 |
|
Parent |
199720 |
Oct 1980 |
|